Resources for switching to denosumab biosimilar
In August 2024, Sandoz launched Jubbonti (denosumab 60 mg six monthly) and Wyost (denosumab 120 mg monthly). BC PharmaCare promptly followed with a schema for expedient conversion of PharmaCare funded denosumab patients to the bio similar preparations. All patients will require a prescription either written as “denosumab”, “Jubbonti”, or “Wyost” in order to proceed with a switch. Pharmacists will not be permitted to make this switch in the absence of a prescription written in this way.
​
Click here to see a document written for health care providers on guidance for switching to denosumab biosimilars.
Pharmacare Special Authority Criteria in BC For Osteoporosis Drugs
Used for other Indications
​
Pamidronate - Link
For Vancouver
For Kelowna
For Surrey
Local Zoledronic Acid Infusion Clinics
The fax forms below are the IV zoledronic acid prescription and order for infusion by a registered nurse. The pharmacy provides your patient medication counseling, coordinates infusion appointment, checks patient labs and advises on hydration protocol prior to medication infusion.
Note: wet signature required on prescriptions